Status:
TERMINATED
Certolizumab Pegol for Treatment of Adult Greek Patients With Moderate to Severe Crohn's Disease Who Failed Infliximab
Lead Sponsor:
UCB Pharma
Conditions:
Crohn's Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
An open-label multi-center single-cohort study to assess the safety and efficacy of certolizumab pegol for the treatment of signs and symptoms of active Crohn's disease in Greek patients who have prev...
Eligibility Criteria
Inclusion
- • Adult men and women with Crohn's disease previously responsive to infliximab who became non-responsive or intolerant
Exclusion
- Symptomatic obstructive intestinal strictures
- Bowel resection within 4 weeks
- Current total parenteral nutrition
- Short bowel syndrome
- Concomitant disease or pathological condition that could interfere with Crohn's disease or to be harmful for the well being of the patient.
Key Trial Info
Start Date :
April 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2008
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00307931
Start Date
April 1 2007
End Date
August 1 2008
Last Update
August 31 2011
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Heraklion, Crete, Greece
2
Athens, Greece
3
Ioannina, Greece
4
Piraeus, Greece